Editorial FDAでの強引な承認 2016年11月1日 Nature Biotechnology 34, 11 doi: 10.1038/nbt.3733 The US Food and Drug Administration approved a muscular-dystrophy drug against the scientific advice of its own staff and advisors. Despite leadership's attempts to downplay the controversy, doubts now surround standards for accelerated approval. Full text PDF 目次へ戻る
